Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: A cohort study

RD Kehm; JL Hopper; EM John; KA Phillips; RJ MacInnis; GS Dite; RL Milne; Y Liao; N Zeinomar; JA Knight; MC Southey; L Vahdat; N Kornhauser; T Cigler; WK Chung; GG Giles; SA McLachlan; ML Friedlander; PC Weideman; G Glendon; S Nesci; IL Andrulis; SS Buys; MB Daly; MB Terry

Journal article

Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: A cohort study

RD Kehm, JL Hopper, EM John, KA Phillips, RJ MacInnis, GS Dite, RL Milne, Y Liao, N Zeinomar, JA Knight, MC Southey, L Vahdat, N Kornhauser, T Cigler, WK Chung, GG Giles, SA McLachlan, ML Friedlander, PC Weideman, G Glendon Show all

Breast Cancer Research | BMC | Published : 2019

DOI: 10.1186/s13058-019-1135-y

Download PDF

Abstract

Background: The use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced breast cancer risk, but it is not known if this association extends to women at familial or genetic risk. We examined the association between regular NSAID use and breast cancer risk using a large cohort of women selected for breast cancer family history, including 1054 BRCA1 or BRCA2 mutation carriers. Methods: We analyzed a prospective cohort (N = 5606) and a larger combined, retrospective and prospective, cohort (N = 8233) of women who were aged 18 to 79 years, enrolled before June 30, 2011, with follow-up questionnaire data on medication history. The prospective cohort..

View full abstract

University of Melbourne Researchers

Kelly Phillips Author

Robert MacInnis Author

Gillian Dite Author

Roger Milne Author

Related Projects (5)

THE KATHLEEN CUNINGHAM FOUNDATION CONSORTIUM FOR RESEARCH INTO FAMILIAL BREAST CANCER (KCONFAB)

TRANSLATING EVIDENCE INTO PRACTICE: OPTIMISING AND FACILITATING PREVENTION AND SCREENING IN WOMEN WITH A STRONG FAMILY HISTORY OF BREAST CANCER

Optimization models and methods are widely used in decision problems. Incorporating parameter uncertainty is important in constructing repre..

PRECISION PREVENTION – FROM PRIORITY TO REALITY

RISK FACTORS, SCREENING, PROPHYLAXIS AND OUTCOMES IN INDIVIDUALS FROM BREAST CANCER FAMILIES: KCONFAB FOLLOW-UP STUDY

Having a strong family history of breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2,..

How can the risk of breast cancer be reduced in those with a strong family history of the disease?

Having a strong family history for breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2..

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

The six sites of the Breast Cancer Family Registry were supported by grant UM1 CA164920 from the USA National Cancer Institute. This work was also supported by grants to kConFab and the kConFab Follow-Up Study from Cancer Australia [grant numbers 809195, 1100868], the Australian National Breast Cancer Foundation [grant number IF 17 kConFab], the National Health and Medical Research Council [grant numbers 454508, 288704, 145684], the National Institute of Health U.S.A. [grant number 1RO1CA159868], the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia [grant numbers not applicable]. RDK is supported by the National Institutes of Health, National Cancer Institute, Cancer Epidemiology Training Grant [grant number T32-CA009529]. KAP is an Australian National Breast Cancer Foundation Practitioner Fellow.